04
AUG
2011

NWBT Announces Further Expansion Of Clinical Sites In Ongoing Brain Cancer Trial

Posted By :
Comments : Off
Bethesda, Maryland, August 4, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the Company’s ongoing clinical trial of DCVax®immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company also announced that a substantial number of additional...
Read More
08
JUL
2011

Family Foundation Of Business Leader Invests $4.55 Million In Northwest Biotherapeutics For Promising Clinical Trials In The US And Europe

Posted By :
Comments : Off
Investment Follows Recent $3 Million Whitebox Hedge Fund Investment and $25 Million Equity Facility Agreement With Toucan Partners Bethesda, MD, July 8, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (“NWBT”) announced today a $4.55 million equity investment on June 28, 2011, by The Richard M. Schulze Family Foundation (the “Foundation”). The sale of newly issued common stock of the Company to the...
Read More
08
JUN
2011

Northwest Biotherapeutics Announces Change And Expansion Of Management Team

Posted By :
Comments : Off
Northwest Biotherapeutics Announces Change and Expansion of Management Team Bethesda, Maryland, June 8, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has made changes and substantially expanded its management team, adding several highly experienced executives. Ms. Linda Powers, who has served as Chairman of the Board since May 2007, has been appointed Chief Executive Officer. Dr. Anthony Maida, a well known...
Read More
05
JUN
2011

Northwest Biotherapeutics Announces Series Of Financing Arrangements

Posted By :
Comments : Off
$3 Million Initial Funding, and Up To $25 Million Further Funding On Fixed, Favorable Terms Bethesda, Maryland, June 5, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has put in place a series of financing arrangements, including a $3 million investment already received, and access to up to $25 million of further funding on fixed, specified and favorable terms, at such times and in such amounts as the Company...
Read More
25
MAY
2011

Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

Posted By :
Comments : Off
Addition of Clinical Sites Ahead of Projections Bethesda, Maryland, May 25, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax®...
Read More